symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
ELDN,1.53,1.85655,72642,36024003,0,1.08-3.7,-0.02,"Eledon Pharmaceuticals, Inc.",USD,0001404281,US28617K1016,28617K101,NASDAQ Capital Market,NASDAQ,Biotechnology,https://eledon.com,"Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.","Dr. David-Alexandre C. Gros M.D., Ph.D.",Healthcare,US,17,949 238 8090,19900 MacArthur Boulevard,Irvine,CA,92612,,0,https://financialmodelingprep.com/image-stock/ELDN.png,2014-09-17,False,False,True,False,False
